Brief: Neurizon Therapeutics Posts Loss For Half Year Attributable Of A$5.5 Million
25/02/2026 01:46
Feb 25 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX: LOSS FOR HALF YEAR ATTRIBUTABLE A$5.5 MILLION HY OTHER INCOME A$6 MILLION Further company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility